Argentinean Registry of heart failure with preserved ejection fraction: ArFey-Preser

Comité de Insuficiencia Cardíaca e Hipertensión Pulmonar de la Federación Argentina de Cardiología

Abstract

Heart failure (HF) with preserved ejection fraction (HFpEF) accounts for more than half of HF cases in the hospital setting as well as in the outpatient setting. Its prevalence is increasing due to the aging of the population and the high rate of obesity, diabetes mellitus, chronic kidney disease
and arterial hypertension. In Argentina, the available data specifically on HFpEF derive from sub-analyses of previous HF registries, with a proportion of less than one third of cases. With the hypothesis that diagnostic and therapeutic strategies in HFpEF in Argentina are suboptimal with an impact on the evolution, Heart Failure and Pulmonary Hypertension Committee from Argentine Federation of Cardiology designed this multicenter, prospective, observational registry. Its primary objectives are to assess the clinical characteristics and management of HFpEF and to analyze the incidence of the combined end point of all cause death or new hospitalization for HF at 1-year follow-up as well as total mortality. The population to be included must meet the following criteria: signs and symptoms of HF, LV ejection fraction ≥50%, and evidence of structural heart disease (ventricular hypertrophy, left atrial dilatation, or evidence of increased LV filling pressures) or elevated natriuretic peptides. The information obtained from this registry will allow to specify the status of this specific
phenotype to design future strategies. With the hypothesis that diagnostic and therapeutic strategies in HFpEF in Argentina are suboptimal with an impact on the evolution, Heart Failure and Pulmonary Hypertension Committee from Argentine Federation of Cardiology designed this multicenter, prospective, observational registry. Its primary objectives are to assess the clinical characteristics and management of HFpEF and to analyze the incidence of the combined end point of all cause death or new hospitalization for HF at 1-year follow-up as well as total mortality. The population to be included must meet the following criteria: signs and symptoms of HF, LV ejection fraction ≥50%, and evidence of structural heart disease (ventricular hypertrophy, left atrial dilatation, or evidence of increased LV filling pressures) or elevated natriuretic peptides. The information obtained from this registry will allow to specify the status of this specific phenotype to design future strategies.